An Interaction Between Levodopa and Enteral Nutrition Resulting in Neuroleptic Malignant-Like Syndrome and Prolonged ICU Stay
Identifieur interne : 000393 ( PascalFrancis/Checkpoint ); précédent : 000392; suivant : 000394An Interaction Between Levodopa and Enteral Nutrition Resulting in Neuroleptic Malignant-Like Syndrome and Prolonged ICU Stay
Auteurs : André Bonnici [Canada] ; Carola-Ellen Ruiner [Canada] ; Lyne St-Laurent [Canada] ; David Hornstein [Canada]Source :
- The Annals of pharmacotherapy [ 1060-0280 ] ; 2010.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
Abstract
OBJECTIVE: To describe a probable interaction between enteral feeds and levodopa leading to neuroleptic malignant-like syndrome (NMLS) in a polytrauma patient with Parkinson's disease (PD). CASE SUMMARY: A 63-year-old morbidly obese male polytrauma patient with PD and type 2 diabetes mellitus was admitted to our intensive care unit postoperatively. Enteral feeds were administered per nasogastric tube and provided 0.88 g /kg/day of protein based on ideal body weight (IBW). His PD medications (pramipexole, entacapone, and immediate-release levodopa/carbidopa 100 mg/25 mg, 1.5 tablets 4 times daily) were administered via nasogastric tube. To achieve better glycemic control, his enteral feeds were changed to a formula that provided 1.8 g/kg/day of protein based on IBW. In the following 24 hours, the patient's mental status deteriorated and he was reintubated. He developed a high fever (40.5 °C), leukocytosis, elevated serum creatine kinase (CK) (480-1801 units/L), and acute renal impairment. His enteral nutrition was changed to decrease protein intake to 1.0 g/kg/day based on IBW and he was given bromocriptine 5 mg 3 times daily via nasogastric tube. Within 24 hours, the patient's mental status improved, his temperature and CK decreased, and his renal function began to improve; the values returned to baseline levels on the 18th day of admission. DISCUSSION: Withdrawal or dose reduction of levodopa in patients with PD has been reported to precipitate NMLS, which is potentially fatal. Because dietary protein can decrease the absorp0tion of levodopa, a potential for an interaction between levodopa and enteral feedings exists, although published reports of such an interaction are limited. In this patient, the likelihood that a drug-nutrient interaction occurred between levodopa and enteral feedings is considered to be probable based on the Naranjo probability scale and the Horn Drug Interaction Probability Scale. CONCLUSIONS: Health-care professionals should be aware of the interaction between levodopa and protein content of enteral nutrition to avoid the occurrence of NMLS in patients with PD.
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
Pascal:10-0439685Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">An Interaction Between Levodopa and Enteral Nutrition Resulting in Neuroleptic Malignant-Like Syndrome and Prolonged ICU Stay</title><author><name sortKey="Bonnici, Andre" sort="Bonnici, Andre" uniqKey="Bonnici A" first="André" last="Bonnici">André Bonnici</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>McGill University Health Centre, Université de Montréal</s1><s2>Montreal, Quebec</s2><s3>CAN</s3><sZ>1 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Montreal, Quebec</wicri:noRegion></affiliation></author><author><name sortKey="Ruiner, Carola Ellen" sort="Ruiner, Carola Ellen" uniqKey="Ruiner C" first="Carola-Ellen" last="Ruiner">Carola-Ellen Ruiner</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Faculty of Medicine, McGill University and McGill University Health Centre</s1><s3>CAN</s3><sZ>2 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Faculty of Medicine, McGill University and McGill University Health Centre</wicri:noRegion></affiliation></author><author><name sortKey="St Laurent, Lyne" sort="St Laurent, Lyne" uniqKey="St Laurent L" first="Lyne" last="St-Laurent">Lyne St-Laurent</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Clinical Nutrition, McGill University Health Centre</s1><s3>CAN</s3><sZ>3 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Department of Clinical Nutrition, McGill University Health Centre</wicri:noRegion></affiliation></author><author><name sortKey="Hornstein, David" sort="Hornstein, David" uniqKey="Hornstein D" first="David" last="Hornstein">David Hornstein</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Department of Medicine, Faculty of Medicine, McGill University; Internal Medicine and Critical Care, SMBD Jewish General Hospital, and McGill University Health Center, Montreal General Hospital</s1><s3>CAN</s3><sZ>4 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Department of Medicine, Faculty of Medicine, McGill University; Internal Medicine and Critical Care, SMBD Jewish General Hospital, and McGill University Health Center, Montreal General Hospital</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">10-0439685</idno><date when="2010">2010</date><idno type="stanalyst">PASCAL 10-0439685 INIST</idno><idno type="RBID">Pascal:10-0439685</idno><idno type="wicri:Area/PascalFrancis/Corpus">000393</idno><idno type="wicri:Area/PascalFrancis/Curation">000884</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000393</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000393</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">An Interaction Between Levodopa and Enteral Nutrition Resulting in Neuroleptic Malignant-Like Syndrome and Prolonged ICU Stay</title><author><name sortKey="Bonnici, Andre" sort="Bonnici, Andre" uniqKey="Bonnici A" first="André" last="Bonnici">André Bonnici</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>McGill University Health Centre, Université de Montréal</s1><s2>Montreal, Quebec</s2><s3>CAN</s3><sZ>1 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Montreal, Quebec</wicri:noRegion></affiliation></author><author><name sortKey="Ruiner, Carola Ellen" sort="Ruiner, Carola Ellen" uniqKey="Ruiner C" first="Carola-Ellen" last="Ruiner">Carola-Ellen Ruiner</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Faculty of Medicine, McGill University and McGill University Health Centre</s1><s3>CAN</s3><sZ>2 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Faculty of Medicine, McGill University and McGill University Health Centre</wicri:noRegion></affiliation></author><author><name sortKey="St Laurent, Lyne" sort="St Laurent, Lyne" uniqKey="St Laurent L" first="Lyne" last="St-Laurent">Lyne St-Laurent</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Clinical Nutrition, McGill University Health Centre</s1><s3>CAN</s3><sZ>3 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Department of Clinical Nutrition, McGill University Health Centre</wicri:noRegion></affiliation></author><author><name sortKey="Hornstein, David" sort="Hornstein, David" uniqKey="Hornstein D" first="David" last="Hornstein">David Hornstein</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Department of Medicine, Faculty of Medicine, McGill University; Internal Medicine and Critical Care, SMBD Jewish General Hospital, and McGill University Health Center, Montreal General Hospital</s1><s3>CAN</s3><sZ>4 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Department of Medicine, Faculty of Medicine, McGill University; Internal Medicine and Critical Care, SMBD Jewish General Hospital, and McGill University Health Center, Montreal General Hospital</wicri:noRegion></affiliation></author></analytic><series><title level="j" type="main">The Annals of pharmacotherapy</title><title level="j" type="abbreviated">Ann. pharmacother.</title><idno type="ISSN">1060-0280</idno><imprint><date when="2010">2010</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">The Annals of pharmacotherapy</title><title level="j" type="abbreviated">Ann. pharmacother.</title><idno type="ISSN">1060-0280</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Enteral administration</term><term>Human</term><term>Interaction</term><term>Levodopa</term><term>Malignant syndrome</term><term>Parkinson disease</term><term>Prolonged</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Interaction</term><term>Lévodopa</term><term>Voie entérale</term><term>Syndrome malin</term><term>Prolongé</term><term>Maladie de Parkinson</term><term>Homme</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">OBJECTIVE: To describe a probable interaction between enteral feeds and levodopa leading to neuroleptic malignant-like syndrome (NMLS) in a polytrauma patient with Parkinson's disease (PD). CASE SUMMARY: A 63-year-old morbidly obese male polytrauma patient with PD and type 2 diabetes mellitus was admitted to our intensive care unit postoperatively. Enteral feeds were administered per nasogastric tube and provided 0.88 g /kg/day of protein based on ideal body weight (IBW). His PD medications (pramipexole, entacapone, and immediate-release levodopa/carbidopa 100 mg/25 mg, 1.5 tablets 4 times daily) were administered via nasogastric tube. To achieve better glycemic control, his enteral feeds were changed to a formula that provided 1.8 g/kg/day of protein based on IBW. In the following 24 hours, the patient's mental status deteriorated and he was reintubated. He developed a high fever (40.5 °C), leukocytosis, elevated serum creatine kinase (CK) (480-1801 units/L), and acute renal impairment. His enteral nutrition was changed to decrease protein intake to 1.0 g/kg/day based on IBW and he was given bromocriptine 5 mg 3 times daily via nasogastric tube. Within 24 hours, the patient's mental status improved, his temperature and CK decreased, and his renal function began to improve; the values returned to baseline levels on the 18th day of admission. DISCUSSION: Withdrawal or dose reduction of levodopa in patients with PD has been reported to precipitate NMLS, which is potentially fatal. Because dietary protein can decrease the absorp0tion of levodopa, a potential for an interaction between levodopa and enteral feedings exists, although published reports of such an interaction are limited. In this patient, the likelihood that a drug-nutrient interaction occurred between levodopa and enteral feedings is considered to be probable based on the Naranjo probability scale and the Horn Drug Interaction Probability Scale. CONCLUSIONS: Health-care professionals should be aware of the interaction between levodopa and protein content of enteral nutrition to avoid the occurrence of NMLS in patients with PD.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>1060-0280</s0></fA01><fA02 i1="01"><s0>APHRER</s0></fA02><fA03 i2="1"><s0>Ann. pharmacother.</s0></fA03><fA05><s2>44</s2></fA05><fA06><s2>9</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>An Interaction Between Levodopa and Enteral Nutrition Resulting in Neuroleptic Malignant-Like Syndrome and Prolonged ICU Stay</s1></fA08><fA11 i1="01" i2="1"><s1>BONNICI (André)</s1></fA11><fA11 i1="02" i2="1"><s1>RUINER (Carola-Ellen)</s1></fA11><fA11 i1="03" i2="1"><s1>ST-LAURENT (Lyne)</s1></fA11><fA11 i1="04" i2="1"><s1>HORNSTEIN (David)</s1></fA11><fA14 i1="01"><s1>McGill University Health Centre, Université de Montréal</s1><s2>Montreal, Quebec</s2><s3>CAN</s3><sZ>1 aut.</sZ></fA14><fA14 i1="02"><s1>Faculty of Medicine, McGill University and McGill University Health Centre</s1><s3>CAN</s3><sZ>2 aut.</sZ></fA14><fA14 i1="03"><s1>Department of Clinical Nutrition, McGill University Health Centre</s1><s3>CAN</s3><sZ>3 aut.</sZ></fA14><fA14 i1="04"><s1>Department of Medicine, Faculty of Medicine, McGill University; Internal Medicine and Critical Care, SMBD Jewish General Hospital, and McGill University Health Center, Montreal General Hospital</s1><s3>CAN</s3><sZ>4 aut.</sZ></fA14><fA20><s1>1504-1507</s1></fA20><fA21><s1>2010</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>13925</s2><s5>354000194257850180</s5></fA43><fA44><s0>0000</s0><s1>© 2010 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>15 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>10-0439685</s0></fA47><fA60><s1>P</s1><s3>EC</s3></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>The Annals of pharmacotherapy</s0></fA64><fA66 i1="01"><s0>USA</s0></fA66><fC01 i1="01" l="ENG"><s0>OBJECTIVE: To describe a probable interaction between enteral feeds and levodopa leading to neuroleptic malignant-like syndrome (NMLS) in a polytrauma patient with Parkinson's disease (PD). CASE SUMMARY: A 63-year-old morbidly obese male polytrauma patient with PD and type 2 diabetes mellitus was admitted to our intensive care unit postoperatively. Enteral feeds were administered per nasogastric tube and provided 0.88 g /kg/day of protein based on ideal body weight (IBW). His PD medications (pramipexole, entacapone, and immediate-release levodopa/carbidopa 100 mg/25 mg, 1.5 tablets 4 times daily) were administered via nasogastric tube. To achieve better glycemic control, his enteral feeds were changed to a formula that provided 1.8 g/kg/day of protein based on IBW. In the following 24 hours, the patient's mental status deteriorated and he was reintubated. He developed a high fever (40.5 °C), leukocytosis, elevated serum creatine kinase (CK) (480-1801 units/L), and acute renal impairment. His enteral nutrition was changed to decrease protein intake to 1.0 g/kg/day based on IBW and he was given bromocriptine 5 mg 3 times daily via nasogastric tube. Within 24 hours, the patient's mental status improved, his temperature and CK decreased, and his renal function began to improve; the values returned to baseline levels on the 18th day of admission. DISCUSSION: Withdrawal or dose reduction of levodopa in patients with PD has been reported to precipitate NMLS, which is potentially fatal. Because dietary protein can decrease the absorp0tion of levodopa, a potential for an interaction between levodopa and enteral feedings exists, although published reports of such an interaction are limited. In this patient, the likelihood that a drug-nutrient interaction occurred between levodopa and enteral feedings is considered to be probable based on the Naranjo probability scale and the Horn Drug Interaction Probability Scale. CONCLUSIONS: Health-care professionals should be aware of the interaction between levodopa and protein content of enteral nutrition to avoid the occurrence of NMLS in patients with PD.</s0></fC01><fC02 i1="01" i2="X"><s0>002B02</s0></fC02><fC02 i1="02" i2="X"><s0>002B17G</s0></fC02><fC02 i1="03" i2="X"><s0>002B17A01</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Interaction</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Interaction</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Interacción</s0><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Lévodopa</s0><s2>NK</s2><s2>FR</s2><s5>02</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Levodopa</s0><s2>NK</s2><s2>FR</s2><s5>02</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Levodopa</s0><s2>NK</s2><s2>FR</s2><s5>02</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Voie entérale</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Enteral administration</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Vía enteral</s0><s5>03</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Syndrome malin</s0><s5>04</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Malignant syndrome</s0><s5>04</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Síndrome maligno</s0><s5>04</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Prolongé</s0><s5>05</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Prolonged</s0><s5>05</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Prolongado</s0><s5>05</s5></fC03><fC03 i1="06" i2="X" l="FRE"><s0>Maladie de Parkinson</s0><s2>NM</s2><s5>06</s5></fC03><fC03 i1="06" i2="X" l="ENG"><s0>Parkinson disease</s0><s2>NM</s2><s5>06</s5></fC03><fC03 i1="06" i2="X" l="SPA"><s0>Parkinson enfermedad</s0><s2>NM</s2><s5>06</s5></fC03><fC03 i1="07" i2="X" l="FRE"><s0>Homme</s0><s5>07</s5></fC03><fC03 i1="07" i2="X" l="ENG"><s0>Human</s0><s5>07</s5></fC03><fC03 i1="07" i2="X" l="SPA"><s0>Hombre</s0><s5>07</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Agoniste</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Agonist</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Agonista</s0><s5>37</s5></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Récepteur dopaminergique D2</s0><s5>38</s5></fC07><fC07 i1="02" i2="X" l="ENG"><s0>D2 Dopamine receptor</s0><s5>38</s5></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Receptor dopaminérgico D2</s0><s5>38</s5></fC07><fC07 i1="03" i2="X" l="FRE"><s0>Antiparkinsonien</s0><s5>39</s5></fC07><fC07 i1="03" i2="X" l="ENG"><s0>Antiparkinson agent</s0><s5>39</s5></fC07><fC07 i1="03" i2="X" l="SPA"><s0>Antiparkinsoniano</s0><s5>39</s5></fC07><fC07 i1="04" i2="X" l="FRE"><s0>Maladie dégénérative</s0><s5>40</s5></fC07><fC07 i1="04" i2="X" l="ENG"><s0>Degenerative disease</s0><s5>40</s5></fC07><fC07 i1="04" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0><s5>40</s5></fC07><fC07 i1="05" i2="X" l="FRE"><s0>Pathologie du système nerveux</s0><s5>41</s5></fC07><fC07 i1="05" i2="X" l="ENG"><s0>Nervous system diseases</s0><s5>41</s5></fC07><fC07 i1="05" i2="X" l="SPA"><s0>Sistema nervioso patología</s0><s5>41</s5></fC07><fC07 i1="06" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0><s5>42</s5></fC07><fC07 i1="06" i2="X" l="ENG"><s0>Cerebral disorder</s0><s5>42</s5></fC07><fC07 i1="06" i2="X" l="SPA"><s0>Encéfalo patología</s0><s5>42</s5></fC07><fC07 i1="07" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0><s5>43</s5></fC07><fC07 i1="07" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0><s5>43</s5></fC07><fC07 i1="07" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0><s5>43</s5></fC07><fC07 i1="08" i2="X" l="FRE"><s0>Pathologie du système nerveux central</s0><s5>44</s5></fC07><fC07 i1="08" i2="X" l="ENG"><s0>Central nervous system disease</s0><s5>44</s5></fC07><fC07 i1="08" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0><s5>44</s5></fC07><fN21><s1>284</s1></fN21><fN44 i1="01"><s1>OTO</s1></fN44><fN82><s1>OTO</s1></fN82></pA></standard></inist><affiliations><list><country><li>Canada</li></country></list><tree><country name="Canada"><noRegion><name sortKey="Bonnici, Andre" sort="Bonnici, Andre" uniqKey="Bonnici A" first="André" last="Bonnici">André Bonnici</name></noRegion><name sortKey="Hornstein, David" sort="Hornstein, David" uniqKey="Hornstein D" first="David" last="Hornstein">David Hornstein</name><name sortKey="Ruiner, Carola Ellen" sort="Ruiner, Carola Ellen" uniqKey="Ruiner C" first="Carola-Ellen" last="Ruiner">Carola-Ellen Ruiner</name><name sortKey="St Laurent, Lyne" sort="St Laurent, Lyne" uniqKey="St Laurent L" first="Lyne" last="St-Laurent">Lyne St-Laurent</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PascalFrancis/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000393 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/biblio.hfd -nk 000393 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= PascalFrancis
|étape= Checkpoint
|type= RBID
|clé= Pascal:10-0439685
|texte= An Interaction Between Levodopa and Enteral Nutrition Resulting in Neuroleptic Malignant-Like Syndrome and Prolonged ICU Stay
}}
| This area was generated with Dilib version V0.6.29. |  |